Reports
Topics
- Accountability 4
- Availability 1
- Care home 2
- Competition 1
- Conflicts of Interest 1
- Conflicts of interest in Healthcare 3
- Contracting 5
- Covid-19 4
- DHSC 1
- Governance 1
- Government’s response to the COVID 19 pandemic 3
- Healthcare Fraud 2
- Inflation 1
- Joint venture 1
- Marketisation 5
- NHS & Social Care Funding 4
- NHS Trusts 1
- OHID 1
- PFI 3
- PHE 1
- Pandemic 1
- Patient Safety 1
- Patient Safety in Private Hospitals 4
- Patient involvement 2
- Preparing for a pandemic 2
- Private Finance Initaitive 5
- Professionalism in Healthcare 1
- Public Health 2
- STPs 5
- Service reconfiguration 3
- Social Care 1
- The finances of the care home sector 4
- The funding gap 3
- The outsourcing of NHS eye care to the private sector 2
- UKHSA 1
Who decides the price and availability of NHS medicines?
Outrage and dismay over the prices charged for new medicines are becoming an increasingly regular occurrence in England. Most recently it was over a life-extending drug for cystic fibrosis, Orkambi, with a hefty price tag of £105,000 per patient per year – far higher than NHS England’s counter offer of £500m over 5 years across all patients.